Financing for the gutOne of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were … more ➔
AMR Report: Test before you treatThe long awaited global review on antimicrobial resistance by economist Lord Jim ONeill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics … more ➔
CRISPR patent deal for BayerBayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one … more ➔
€21.5m for Oxford stem cell spinoutNewly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic … more ➔
€39m for neurodegeneration therapiesSwiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimers disease. The news follows a recently announced R&D … more ➔
Ipsen and Oncodesign partner in R&DIpsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research … more ➔
US$471m for cancer research fundSwiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes … more ➔
Clinical trial disaster: report blames dru...An expert panels final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drugs toxicity and not by any violation … more ➔
Argenx in cancer drug licensing dealFor up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive … more ➔
Swiss biotech continues to do wellDespite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new … more ➔
